[Is overweight in patients with type 1 diabetes in the puberty a problem?].
AIM OF THE STUDY was the appreciation of the body mass index (BMI) of adolescents with diabetes type 1 treated with different methods of insulin therapy as well as the correlation of the BMI with the age of the patients, duration of the diabetes therapy and with the metabolic control.


METHODS
The examinations included 205 patients aged 14 to 18 years (X 16.8). The examined group consisted of 112 girls (54.5%) and 93 boys (45.5%). In all the patients the body mass index (BMI) was calculated HbA1c, total cholesterol, HDL, LDL, triglyceride the duration and method of therapy of diabetes were determined. The patients were divided in 4 groups. Group 1 and 3 included patients treated with insulin in multiple daily doses (4-5 doses). Group 1 included 49 girls, group 3-36 boys. In group 2 and 4 there were patients treated with intensive therapy with insulin analogs (Humalog, NOVO Rapid) and NPH insulin. In group 2 there were 63 girls, in group 4 -57 boys.


RESULTS
In the groups of boys higher statistically significant levels of HbA1c were observed in those treated with multiple daily doses (gr. 3), the body mass index was higher in boys treated with insulin analogs (gr. 4) [p<0.05, vs p<0.05].


CONCLUSIONS
1. The therapy of diabetes type 1 in the puberty with multiple daily doses as well as with the intensive method is not a risk factor for obesity. 2. Normal weight evidenced a proper diabetic metabolic control and a good education about the rational diet and optimal insulin dose. 3. In patients in whom BMI is over normal range it is urgently necessary to verify of the therapeutical management. 4. In patients with diabetes type 1 a strict control of body mass index and the growth velocity during each visit in the out patients is necessary.
Katedra i Klinika Endokrynologii Wieku Rozwojowego AM we Wrocławiu, Wrocław, Poland.
Anna
A
Noczyńska
Henryk
H
Filipowski
Renata
R
Wasikowa
D000293:Adolescent; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D018450:Disease Progression; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D008297:Male; D009765:Obesity; D011044:Poland; D011627:Puberty; D012307:Risk Factors; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D002784:Cholesterol; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D014280:Triglycerides